Literature DB >> 31692036

Genome-wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma.

Furong Liu1,2,3, Zhibin Liao1,2, Jia Song1,2, Chaoyi Yuan1,2, Yachong Liu1,2, Hongwei Zhang1,2, Yonglong Pan1,2, Zhanguo Zhang1,2, Bixiang Zhang1,2.   

Abstract

Although methods in diagnosis and therapy of hepatocellular carcinoma (HCC) have made significant progress in decades, the overall survival (OS) of HCC remains dissatisfactory, so it is particularly important to find better diagnostic and prognostic biomarkers. In this study, we found a more reliable potential diagnostic biomarkers and constructed a more accurate prognostic evaluation model based on integrated transcriptome sequencing analysis of multiple independent data sets. First, we performed quality evaluation and differential analysis on seven Gene Expression Omnibus (GEO) data sets, and then comprehensively analyzed the differentially expressed genes with a robust rank aggregation algorithm. Next, Least absolute shrinkage and selection operator (LASSO) regression was used to establish an 8-gene prognostic risk score (RS) model. Finally, the prognostic model was further validated in the GEO data set. Also, RS has independence on other clinicopathological characteristics but has similarities in prognostic assessment compared with the T stage. Moreover, the combination of T stage and prognostic RS model based on the 8-gene had a better prognostic evaluation effect. In brief, our research suggest that the prognostic risk model of 8 genes has important clinical significance in HCC patients, and can further enrich the prognostic guidance value of the traditional T stage.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  diagnostic biomarkers; hepatocellular carcinoma (HCC); prognostic model

Mesh:

Substances:

Year:  2019        PMID: 31692036     DOI: 10.1002/jcb.29480

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Identification and Validation of a GPX4-Related Immune Prognostic Signature for Lung Adenocarcinoma.

Authors:  Zhenxing Feng; Bo Li; Qingliang Chen; Hong Zhang; Zhigang Guo; Jianwen Qin
Journal:  J Oncol       Date:  2022-05-17       Impact factor: 4.501

2.  CD44, IL-33, and ST2 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility in the Chinese Population.

Authors:  Xiaolan Pan; Meiqin Li; Lei Huang; Dan Mo; Yihua Liang; Zhaodong Huang; Bo Zhu; Min Fang
Journal:  Biomed Res Int       Date:  2020-09-29       Impact factor: 3.411

3.  Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer.

Authors:  Penghui Yuan; Le Ling; Xintao Gao; Taotao Sun; Jianping Miao; Xianglin Yuan; Jihong Liu; Zhihua Wang; Bo Liu
Journal:  Aging (Albany NY)       Date:  2021-01-15       Impact factor: 5.682

4.  Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis.

Authors:  Di Wu; Yun Pan; Xueyong Zheng
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

5.  Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

6.  Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Cell Mol Med       Date:  2020-12-09       Impact factor: 5.295

7.  Characterization of TGFβ-associated molecular features and drug responses in gastrointestinal adenocarcinoma.

Authors:  Qiaofeng Zhang; Furong Liu; Lu Qin; Zhibin Liao; Jia Song; Huifang Liang; Xiaoping Chen; Zhanguo Zhang; Bixiang Zhang
Journal:  BMC Gastroenterol       Date:  2021-07-12       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.